DOD Peer Reviewed Cancer, Impact Award
ID: 359098Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Peer Reviewed Cancer Research Program (PRCRP) Impact Award to support high-impact research aimed at improving clinical cancer care relevant to military health. This grant seeks mature research projects that demonstrate potential for near-term benefits in cancer treatment and patient outcomes, particularly focusing on specific cancer types such as bladder, blood, and brain cancers, while excluding melanoma and breast cancers. The program emphasizes the importance of preliminary data, collaboration with Department of Defense (DOD) and Veterans Affairs (VA) entities, and rigorous study designs to advance cancer detection and treatment for service members and their families. The estimated total program funding is $45.5 million, with individual awards capped at $1.4 million for single Principal Investigator applications and $1.75 million for partnering applications, over a maximum period of three years. Interested applicants must submit a pre-application by September 25, 2025, and can contact the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense (DOD) is announcing the FY25 Peer Reviewed Cancer Research Program (PRCRP) Impact Award, aimed at funding high-impact research with near-term benefits for clinical cancer care relevant to military health. Eligible applicants include organizations, independent investigators, and partnerships, with funding capped at $1.4 million for single Principal Investigator (PI) applications and $1.75 million for partnering applications over a maximum period of three years. The program prioritizes research on specific cancer types such as bladder, blood, and brain cancers, while excluding melanoma and breast cancers. A two-step application process involves a pre-application and a full application, with important deadlines set for 2025. The award seeks to support mature research that demonstrates potential to improve patient outcomes through rigorous study designs. Emphasis is placed on producing preliminary data, maintaining relevance to military health needs, and fostering collaborations with DOD and VA entities. These criteria are essential for driving advancements in cancer detection, treatment, and survivorship for service members and their families, aligning with the overarching mission to decrease the cancer burden within military populations.
    Similar Opportunities
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity for the Staff Research Program, aimed at engaging scientific staff in collaborative research with higher education institutions. This program seeks to enhance the professional competence of Army Research Office (ARO) scientists through hands-on, fundamental research in various scientific fields, including engineering, physical sciences, and life sciences, with a focus on advancing knowledge relevant to Army missions. Eligible applicants include institutions recognized for their scientific research capabilities, and the funding will be provided through cooperative agreements with award amounts ranging from $200,000 to $10 million. Proposals must be submitted via Grants.gov by June 2, 2030, and interested parties can contact Mr. William Creech at William.a.creech3.civ@army.mil for further information.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, specifically for the fiscal years 2027, 2028, and 2029, under the P50 Clinical Trial Required grant program. This initiative aims to fund innovative translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups, utilizing advanced cellular, molecular, and genetic approaches. With an estimated total program funding of $25 million and the expectation of awarding 12 grants, interested applicants must submit their proposals by January 25, 2027, with the anticipated award date set for June 4, 2027. For further inquiries, applicants can contact Bradley T. Scroggins at bradley.scroggins@nih.gov or by phone at 240-276-7860.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers, aimed at supporting innovative translational research from 2024 to 2026. This initiative invites applications for P50 Research Center Grants that focus on enhancing cancer prevention, early detection, diagnosis, and treatment, particularly for organ-specific cancers or related groups, with a requirement for at least one clinical trial component in each application. The program is crucial for advancing cancer research and addressing health disparities, with funding available up to $1,400,000 in direct costs per year over a five-year project period. Interested applicants can find more information and application guidelines at the NIH website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for September 25, 2026.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.